Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan
Abstract Background Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population. Methods To evaluate the effects...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14786 |
| _version_ | 1811160931755884544 |
|---|---|
| author | Yuan‐Hung Wu Yu‐Mei Kang Yu‐Wen Hu Keng‐Li Lan Sang‐Hue Yen Tzu‐Yu Lai Tien‐Li Lan Yuh‐Min Chen Chao‐Hua Chiu Yung‐Hung Luo Heng‐sheng Chao Chi‐Lu Chiang Tsu‐Hui Shiao Chao‐Neng Yang Wen‐Hu Hsu Yu‐Chung Wu Han‐Shui Hsu Jung‐Jyh Hung Chien‐Sheng Huang Po‐Kuei Hsu Yi‐Wei Chen |
| author_facet | Yuan‐Hung Wu Yu‐Mei Kang Yu‐Wen Hu Keng‐Li Lan Sang‐Hue Yen Tzu‐Yu Lai Tien‐Li Lan Yuh‐Min Chen Chao‐Hua Chiu Yung‐Hung Luo Heng‐sheng Chao Chi‐Lu Chiang Tsu‐Hui Shiao Chao‐Neng Yang Wen‐Hu Hsu Yu‐Chung Wu Han‐Shui Hsu Jung‐Jyh Hung Chien‐Sheng Huang Po‐Kuei Hsu Yi‐Wei Chen |
| author_sort | Yuan‐Hung Wu |
| collection | DOAJ |
| description | Abstract Background Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population. Methods To evaluate the effects of old age and EGFR mutation on treatment outcomes and toxicity, we reviewed the medical records of 71 consecutive patients with inoperable early‐stage non‐small cell lung cancer (NSCLC) who received SABR at Taipei Veterans General Hospital between 2015 and 2021. Results The study revealed that median age, follow‐up, Charlson comorbidity index, and ECOG score were 80 years, 2.48 years, 3, and 1, respectively. Of these patients, 37 (52.1%) were 80 years or older, and 50 (70.4%) and 21 (29.6%) had T1 and T2 diseases, respectively. EGFR mutation status was available for 33 (46.5%) patients, of whom 16 (51.5%) had a mutation. The overall survival rates at 1, 3, and 5 years were 97.2, 74.9, and 58.3%, respectively. The local control rate at 1, 3, and 5 years was 97.1, 92.5, and 92.5%, respectively. Using Cox proportional hazards regression we found that male sex was a risk factor for overall survival (p = 0.036, 95% CI: 1.118–26.188). Two patients had grade 2 pneumonitis, but no other grade 2 or higher toxicity was observed. We did not find any significant differences in treatment outcomes or toxicity between patients aged 80 or older and those with EGFR mutations in this cohort. Conclusion These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early‐stage NSCLC. |
| first_indexed | 2024-04-10T06:06:06Z |
| format | Article |
| id | doaj.art-5b089288371243c5a3bbf99975a9d3fc |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-10T06:06:06Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-5b089288371243c5a3bbf99975a9d3fc2023-03-03T00:09:57ZengWileyThoracic Cancer1759-77061759-77142023-03-0114765466110.1111/1759-7714.14786Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in TaiwanYuan‐Hung Wu0Yu‐Mei Kang1Yu‐Wen Hu2Keng‐Li Lan3Sang‐Hue Yen4Tzu‐Yu Lai5Tien‐Li Lan6Yuh‐Min Chen7Chao‐Hua Chiu8Yung‐Hung Luo9Heng‐sheng Chao10Chi‐Lu Chiang11Tsu‐Hui Shiao12Chao‐Neng Yang13Wen‐Hu Hsu14Yu‐Chung Wu15Han‐Shui Hsu16Jung‐Jyh Hung17Chien‐Sheng Huang18Po‐Kuei Hsu19Yi‐Wei Chen20Department of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanTaipei Cancer Center and Taipei Medical University Hospital Taipei Medical University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanDepartment of Surgery Taipei Veterans General Hospital Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanSchool of Medicine National Yang‐Ming Chiao‐Tung University Taipei TaiwanDepartment of Oncology Taipei Veterans General Hospital Taipei TaiwanAbstract Background Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population. Methods To evaluate the effects of old age and EGFR mutation on treatment outcomes and toxicity, we reviewed the medical records of 71 consecutive patients with inoperable early‐stage non‐small cell lung cancer (NSCLC) who received SABR at Taipei Veterans General Hospital between 2015 and 2021. Results The study revealed that median age, follow‐up, Charlson comorbidity index, and ECOG score were 80 years, 2.48 years, 3, and 1, respectively. Of these patients, 37 (52.1%) were 80 years or older, and 50 (70.4%) and 21 (29.6%) had T1 and T2 diseases, respectively. EGFR mutation status was available for 33 (46.5%) patients, of whom 16 (51.5%) had a mutation. The overall survival rates at 1, 3, and 5 years were 97.2, 74.9, and 58.3%, respectively. The local control rate at 1, 3, and 5 years was 97.1, 92.5, and 92.5%, respectively. Using Cox proportional hazards regression we found that male sex was a risk factor for overall survival (p = 0.036, 95% CI: 1.118–26.188). Two patients had grade 2 pneumonitis, but no other grade 2 or higher toxicity was observed. We did not find any significant differences in treatment outcomes or toxicity between patients aged 80 or older and those with EGFR mutations in this cohort. Conclusion These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early‐stage NSCLC.https://doi.org/10.1111/1759-7714.14786EGFRlung cancerold ageSABR |
| spellingShingle | Yuan‐Hung Wu Yu‐Mei Kang Yu‐Wen Hu Keng‐Li Lan Sang‐Hue Yen Tzu‐Yu Lai Tien‐Li Lan Yuh‐Min Chen Chao‐Hua Chiu Yung‐Hung Luo Heng‐sheng Chao Chi‐Lu Chiang Tsu‐Hui Shiao Chao‐Neng Yang Wen‐Hu Hsu Yu‐Chung Wu Han‐Shui Hsu Jung‐Jyh Hung Chien‐Sheng Huang Po‐Kuei Hsu Yi‐Wei Chen Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan Thoracic Cancer EGFR lung cancer old age SABR |
| title | Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan |
| title_full | Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan |
| title_fullStr | Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan |
| title_full_unstemmed | Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan |
| title_short | Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan |
| title_sort | old age and egfr mutation status in inoperable early stage non small cell lung cancer patients receiving stereotactic ablative radiotherapy a single institute experience of 71 patients in taiwan |
| topic | EGFR lung cancer old age SABR |
| url | https://doi.org/10.1111/1759-7714.14786 |
| work_keys_str_mv | AT yuanhungwu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yumeikang oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yuwenhu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT kenglilan oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT sanghueyen oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT tzuyulai oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT tienlilan oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yuhminchen oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT chaohuachiu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yunghungluo oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT hengshengchao oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT chiluchiang oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT tsuhuishiao oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT chaonengyang oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT wenhuhsu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yuchungwu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT hanshuihsu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT jungjyhhung oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT chienshenghuang oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT pokueihsu oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan AT yiweichen oldageandegfrmutationstatusininoperableearlystagenonsmallcelllungcancerpatientsreceivingstereotacticablativeradiotherapyasingleinstituteexperienceof71patientsintaiwan |